Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting

– Preclinical data demonstrate SER-155 reduces infection and Graft-versus-Host Disease –

Excerpt from the Press Release:

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, will present preclinical findings tomorrow at the European Bone Marrow Transplantation (EBMT) Annual Meeting that suggest SER-155 works by targeting the host immune response, potentially allowing patients undergoing hematopoietic stem cell transplantation (HSCT) to avoid infection or Graft-versus-Host Disease (GvHD), which currently afflict about half of this patient population. SER-155 is being evaluated in an ongoing Phase 1b clinical trial.

“Microbiome-based therapeutics have the potential to protect medically compromised transplant patients from life-threatening infections and GvHD as they start on their road to recovery,” said Matthew Henn, PhD, Chief Scientific Officer at Seres and co-author. “Building on scientific and clinical data from our SER-109 program, we are encouraged by these preclinical findings that bolster our confidence in combating additional important infectious diseases and the continued threat of antimicrobial resistance with further development of SER-155 as a potentially transformative new medicine.”

These results will appear on an e-poster (p194) and will be presented at 9:50 am CET Saturday, March 19, by Elizabeth Halvorsen, PhD, Director of Translational Sciences at Seres.

Click the button below to read the entire Press Release:

Continue Reading The Press Release